FDA approves Regeneron's Livsayis as first quarterly siRNA treatment for generalised myasthenia gravis

Regeneron's first approved siRNA medicine introduces three-monthly subcutaneous treatment for eligible adults with generalised myasthenia gravis, supported by positive Phase III NIMBLE results.
The US Food and Drug Administration approved Regeneron's Livsayis (cemdisiran) on 18 November 2026 for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, establishing a complement C5-directed siRNA treatment administered subcutaneously every three months.
In the Phase III NIMBLE study, Livsayis achieved a placebo-adjusted 2.3-point improvement in Myasthenia Gravis Activities of Daily Living score at week 24 (p=0.0005), with 76.6% of treated patients achieving an improvement of at least three points compared with 44.1% receiving placebo; the approval is separate from the previously reported Klygefa authorisation.
Field | Content |
Company | Regeneron Pharmaceuticals |
Medicine | Livsayis (cemdisiran) |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 18 November 2026 |
Approval Type | New medicine approval |
Therapeutic Area | Neurology and autoimmune neuromuscular disease |
Indication | Anti-acetylcholine receptor antibody-positive generalised myasthenia gravis |
Eligible Population | Adults with AChR antibody-positive generalised myasthenia gravis |
Drug Modality | Small interfering RNA (siRNA) |
Molecular Target | Complement component C5 |
Administration | Subcutaneous injection every three months |
Supporting Trial | Phase III NIMBLE |
Primary Efficacy Finding | Placebo-adjusted 2.3-point improvement in MG-ADL score at week 24; p=0.0005 |
Clinically Meaningful Improvement | 76.6% achieved at least a three-point MG-ADL improvement versus 44.1% with placebo |
Company Milestone | Regeneron's first approved siRNA and neurology medicine |
Regulatory Significance | First quarterly siRNA treatment approved for the specified generalised myasthenia gravis population; distinct from Klygefa |
Primary Source | https://newsroom.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com



Comentarios